1. Home
  2. CLGN vs BIAF Comparison

CLGN vs BIAF Comparison

Compare CLGN & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CollPlant Biotechnologies Ltd

CLGN

CollPlant Biotechnologies Ltd

HOLD

Current Price

$0.31

Market Cap

5.2M

Sector

Health Care

ML Signal

HOLD

Logo bioAffinity Technologies Inc.

BIAF

bioAffinity Technologies Inc.

HOLD

Current Price

$0.39

Market Cap

4.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLGN
BIAF
Founded
2004
2014
Country
Israel
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.2M
4.5M
IPO Year
2015
2022

Fundamental Metrics

Financial Performance
Metric
CLGN
BIAF
Price
$0.31
$0.39
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$11.00
N/A
AVG Volume (30 Days)
53.8K
204.1K
Earning Date
05-27-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$7,900,000.00
Revenue This Year
$240.45
$20.95
Revenue Next Year
$38.03
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
14.49
52 Week Low
$0.27
$0.23
52 Week High
$3.18
$13.50

Technical Indicators

Market Signals
Indicator
CLGN
BIAF
Relative Strength Index (RSI) 46.32 17.50
Support Level $0.29 N/A
Resistance Level $0.44 $0.87
Average True Range (ATR) 0.04 0.05
MACD 0.00 0.00
Stochastic Oscillator 46.96 16.94

Price Performance

Historical Comparison
CLGN
BIAF

About CLGN CollPlant Biotechnologies Ltd

CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.

About BIAF bioAffinity Technologies Inc.

bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.

Share on Social Networks: